Compare AT&T Inc. (T) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? AT&T Inc. trades at $25.26 (market cap $175.42B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: AT&T Inc. is the larger of the two by market cap, and AT&T Inc. pays a 4.34% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| T | VRTX | |
|---|---|---|
Market Cap | $175.42B | $134.06B |
Sector | Media | Health |
52-Week High | $29.62 | $557.96 |
52-Week Low | $20.49 | $376.62 |
Enterprise Value | $320.74B | $128.18B |
Dividend Yield | 4.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $25.61, down slightly by 0.21% on the day. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company reported robust earnings, beating estimates in recent quarters, with a net income margin of 16.94% and attractive valuation ratios like a P/E of 8.45. Recent news highlights strategic focus on fiber and wireless growth, including a partnership with Amazon for satellite broadband.
The outlook for AT&T is positive, supported by consistent earnings beats, a solid dividend, and strategic initiatives in fiber and 5G. Key risks include high debt levels and intense competition. Analysts maintain a consensus buy rating with a $27.69 price target, suggesting potential upside from current levels.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
